COMPANY
Kano Therapeutics
NIH awards 2
- NIH award 4R44GM159495-02 FY2026: $984,281 awarded for that fiscal year; activity R44 (SBIR); PI ENGELHARDT, FLORIS ALASKA SILVIA; recipient as written: KANO THERAPEUTICS INC, CAMBRIDGE, MA. Active non-viral nuclear source ↗
- NIH award 1R44GM159495-01 FY2025: $349,952 awarded for that fiscal year; activity R44 (SBIR); PI ENGELHARDT, FLORIS ALASKA SILVIA; recipient as written: KANO THERAPEUTICS INC, CAMBRIDGE, MA. Active non-viral nuclear source ↗
Funding and NIH signals
- NIH award NIH awarded $984K (SBIR Phase II 4R44GM159495-02, extension, notice Aug 18, 2026). NIH RePORTER 4R44GM159495-02 (Aug 18, 2026)
Evidence (1 event)
- Aug 18, 2026 · NIH RePORTER 4R44GM159495-02
Organization: KANO THERAPEUTICS INC; City/State: CAMBRIDGE, MA; Project number: 4R44GM159495-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 984281; Administering IC: National Institute of General Medical Sciences; Project title: Active non-viral nuclear delivery of DNA templates independent of mitosis; Organization type: Domestic For-Profits
- Aug 18, 2026 · NIH RePORTER 4R44GM159495-02